Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AMER AL-KHOUDARI

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1013036516
CMS profile
506002
Location
CHANDLER, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$64,888.50

342 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 6 of 7; records 251–300 of 342 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AMER AL-KHOUDARI

NPI 1013036516 · CMS profile ID 506002

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

CHANDLER, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 6 of 7; records 251–300 of 342 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1013036516?year=2022&recipient=provider&page=6#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AMER AL-KHOUDARI, NPI 1013036516, CMS profile ID 506002. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 7; records 251–300 of 342 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1013036516?year=2022&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). AMER AL-KHOUDARI, NPI 1013036516, CMS profile ID 506002. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 7; records 251–300 of 342 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1013036516?year=2022&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
AMER AL-KHOUDARI, NPI 1013036516, CMS profile ID 506002, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 7; records 251–300 of 342 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1013036516?year=2022&recipient=provider&page=6#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

342 matching records · $64,888.50 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 342 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 251–300 of 342.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
UCB, Inc. $23.5204/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908048261 CMS
ABBVIE INC. $22.7204/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890475567 CMS
Janssen Biotech, Inc. $21.9404/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885499009 CMS
E.R. Squibb & Sons, L.L.C. $18.3404/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932631053 CMS
ABBVIE INC. $9.1804/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890475565 CMS
GlaxoSmithKline, LLC. $11.5304/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944598655 CMS
Horizon Therapeutics plc $16.2004/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937583043 CMS
Janssen Biotech, Inc. $11.5204/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885498823 CMS
Janssen Biotech, Inc. $3.7204/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885498827 CMS
Horizon Therapeutics plc $8.8503/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937583039 CMS
Amgen Inc. $26.1103/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939270413 CMS
Janssen Biotech, Inc. $16.9603/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885499029 CMS
ABBVIE INC. $25.7503/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890475563 CMS
Horizon Therapeutics plc $1,800.0003/24/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937583033 CMS
Amgen Inc. $6.7503/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939270381 CMS
GlaxoSmithKline, LLC. $6.7203/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944598709 CMS
Janssen Biotech, Inc. $18.5703/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885499025 CMS
Novartis Pharmaceuticals Corporation $16.6403/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893491249 CMS
Janssen Biotech, Inc. $11.2703/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885498807 CMS
Lilly USA, LLC $15.6103/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917857525 CMS
Alexion Pharmaceuticals, Inc. $19.7403/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915066483 CMS
UCB, Inc. $7.5603/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908048245 CMS
ABBVIE INC. $23.1703/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890475561 CMS
UCB, Inc. $1,850.0003/14/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038608407 CMS
Amgen Inc. $8.5403/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939270379 CMS
Janssen Biotech, Inc. $14.3803/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885499021 CMS
E.R. Squibb & Sons, L.L.C. $15.8703/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932631051 CMS
Janssen Biotech, Inc. $9.6803/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885498803 CMS
ABBVIE INC. $58.0003/09/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890475557 CMS
ABBVIE INC. $25.3903/09/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890475559 CMS
Horizon Therapeutics plc $11.7903/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937583029 CMS
ABBVIE INC. $2,000.0003/07/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890475551 CMS
ABBVIE INC. $1,200.0003/07/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890475553 CMS
ABBVIE INC. $2,000.0003/07/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890475555 CMS
Janssen Biotech, Inc. $8.0303/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885498799 CMS
ABBVIE INC. $55.5203/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890475547 CMS
ABBVIE INC. $3,200.0003/02/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890475549 CMS
UCB, Inc. $12.9703/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908048253 CMS
ABBVIE INC. $5.5403/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890475545 CMS
Janssen Biotech, Inc. $6.8803/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885498795 CMS
ABBVIE INC. $187.5802/26/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890475525 CMS
ABBVIE INC. $39.4002/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890475527 CMS
ABBVIE INC. $17.6402/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890475529 CMS
ABBVIE INC. $90.9602/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890475531 CMS
ABBVIE INC. $17.6302/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890475533 CMS
ABBVIE INC. $20.8802/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890475535 CMS
ABBVIE INC. $17.6302/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890475537 CMS
ABBVIE INC. $6.9602/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890475539 CMS
ABBVIE INC. $80.8002/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890475541 CMS
ABBVIE INC. $17.6302/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890475543 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $49,193.33 180
PY2020 $14,420.21 203
PY2021 $27,416.77 281
PY2022 $64,888.50 342
PY2023 $81,640.44 402
PY2024 $68,042.93 373
PY2025 $63,121.49 305

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,578,046.38 25
PY2024 Recipient $20,004.58 2
PY2024 Principal investigator $1,349,225.38 17
PY2023 Recipient $24,641.00 1
PY2023 Principal investigator $6,515.00 1
PY2022 Principal investigator $6,750.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

25 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,395.80 11/07/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288141
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,040.00 11/07/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288143
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 11/07/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288145
Principal investigator 1 SANOFI US SERVICES INC. $3,774.03 09/03/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226083180
Principal investigator 1 UCB SA $16,000.00 08/25/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246659296
Principal investigator 1 ABBVIE INC. $4,080.00 08/21/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202505519
Principal investigator 1 ABBVIE INC. $8,160.00 08/12/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202504273
Principal investigator 1 ABBVIE INC. $4,080.00 08/07/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202504027
Principal investigator 1 Amgen Inc. $85,949.85 08/01/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246639289
Principal investigator 1 Amgen Inc. $573.06 07/28/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS CLINIC - CHANDLER
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246639331
Principal investigator 1 Amgen Inc. $10,000.00 07/16/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) No dispute reported 06/30/2026 1246639265
Principal investigator 1 Eli Lilly and Company $14,000.00 06/23/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187877151
Principal investigator 1 Amgen Inc. $40,999.38 04/25/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants No dispute reported 06/30/2026 1246639305
Principal investigator 1 SANOFI US SERVICES INC. $600.00 04/14/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226083149
Principal investigator 1 ABBVIE INC. $680.00 04/10/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202475691
Principal investigator 1 Amgen Inc. $40,949.90 04/01/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246639243
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,105.00 04/01/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223277284
Principal investigator 1 ABBVIE INC. $3,387.00 03/06/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202456410
Principal investigator 1 Amgen Inc. $4,827.44 02/12/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY ASSOCIATES - TUCSON - 2001 W ORANGE GROVE RD
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246639225
Principal investigator 1 Eli Lilly and Company $1,149.11 01/27/2025 Non-covered Recipient Entity
AARA CLINICAL RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187875055
Principal investigator 1 Eli Lilly and Company $16,400.83 01/22/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187876889
Principal investigator 1 Eli Lilly and Company $32,781.00 01/21/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187873801
Principal investigator 1 Amgen Inc. $1,083.10 01/08/2025 Non-covered Recipient Entity
ARIZONA RESEARCH CLINIC PLLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246639345
Principal investigator 1 Amgen Inc. $543,286.56 01/06/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY ASSOCIATES - TUCSON - 2001 W ORANGE GROVE RD
A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants No dispute reported 06/30/2026 1246639227
Principal investigator 1 Amgen Inc. $727,744.32 01/02/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS CLINIC - CHANDLER
A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants No dispute reported 06/30/2026 1246639335